Literature DB >> 14578734

Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan.

Nestor F Esnaola1, Nadeem Mirza, Gregory Y Lauwers, Iwao Ikai, Jean-Marc Regimbeau, Jacques Belghiti, Yoshio Yamaoka, Steven A Curley, Lee M Ellis, David M Nagorney, Jean-Nicolas Vauthey.   

Abstract

OBJECTIVE: To compare the clinicopathologic characteristics and outcomes after resection of patients with hepatocellular carcinoma (HCC) treated in the United States, France, and Japan. SUMMARY BACKGROUND DATA: Some epidemiologic data suggests that HCC in different regions of the world may represent different forms of the disease.
METHODS: We compared the patient and tumor characteristics, underlying liver damage, and surgical outcomes of 586 patients who underwent resection of HCC from a multi-institutional database.
RESULTS: A total of 169 patients were treated in the United States, 187 in France, and 230 in Japan. The median tumor size for patients treated in the United States was 8 cm, compared with 6 cm and 3.5 cm in France and Japan, respectively (P < 0.001); 20%, 38%, and 74% of patients in the United States, France, and Japan, respectively, had positive hepatitis C serology (P < 0.001). In addition, 65% of patients in Japan had severe fibrosis/cirrhosis in the adjacent liver compared with 52% and 23% of patients in France and the United States, respectively (P < 0.001). There was no association between site of treatment and 30-day (P = 0.4) or 1-year mortality (P = 0.3). The 5-year survival of patients treated in United States, France, and Japan was not statistically different (31% vs. 31% vs. 41%, respectively; P = 0.3).
CONCLUSIONS: Although the etiology of HCC and clinicopathologic characteristics of patients treated at western and eastern centers vary widely, postresection 5-year survival is similar when controlling for these factors. Future studies should account for histopathologic differences using uniform criteria to allow better comparison of results.

Entities:  

Mesh:

Year:  2003        PMID: 14578734      PMCID: PMC1356150          DOI: 10.1097/01.sla.0000094436.34556.ac

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  33 in total

1.  Portal vein evaluation with US: comparison to angiography combined with CT arterial portography.

Authors:  A M Bach; L E Hann; K T Brown; G I Getrajdman; S K Herman; Y Fong; L H Blumgart
Journal:  Radiology       Date:  1996-10       Impact factor: 11.105

2.  Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma.

Authors:  N Yamanaka; T Tanaka; W Tanaka; J Yamanaka; C Yasui; N Kuroda; M Takada; E Okamoto
Journal:  Cancer       Date:  1997-04-15       Impact factor: 6.860

3.  Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma.

Authors:  M F Chen; L B Jeng; W C Lee; T C Chen
Journal:  Surgery       Date:  1998-05       Impact factor: 3.982

4.  An analysis of 412 cases of hepatocellular carcinoma at a Western center.

Authors:  Y Fong; R L Sun; W Jarnagin; L H Blumgart
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

5.  A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.

Authors: 
Journal:  Hepatology       Date:  1998-09       Impact factor: 17.425

6.  Tumor involvement in hepatic veins: comparison of MR imaging and US for preoperative assessment.

Authors:  L E Hann; L H Schwartz; D M Panicek; A M Bach; Y Fong; L H Blumgart
Journal:  Radiology       Date:  1998-03       Impact factor: 11.105

7.  Rising incidence of hepatocellular carcinoma in the United States.

Authors:  H B El-Serag; A C Mason
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

8.  Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma.

Authors:  S Kubo; S Nishiguchi; K Hirohashi; H Tanaka; T Tsukamoto; H Hamba; T Shuto; T Yamamoto; T Ikebe; H Kinoshita
Journal:  Cancer       Date:  1999-09-01       Impact factor: 6.860

9.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

10.  Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection.

Authors:  R Izumi; K Shimizu; T Ii; M Yagi; O Matsui; A Nonomura; I Miyazaki
Journal:  Gastroenterology       Date:  1994-03       Impact factor: 22.682

View more
  20 in total

1.  Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jia Fan; Jian Zhou; Zhi-Quan Wu; Shuang-Jian Qiu; Xiao-Ying Wang; Ying-Hong Shi; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

2.  Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA.

Authors:  Mohamed Abd El-Fattah
Journal:  Indian J Gastroenterol       Date:  2017-02-14

Review 3.  Surgical treatment of hepatocellular carcinoma: expert consensus statement.

Authors:  William Jarnagin; William C Chapman; Steven Curley; Michael D'Angelica; Charles Rosen; Elijah Dixon; David Nagorney
Journal:  HPB (Oxford)       Date:  2010-06       Impact factor: 3.647

4.  The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background.

Authors:  Hui-Chuan Sun; Zhao-You Tang; Zeng-Chen Ma; Lun-Xiu Qin; Lu Wang; Qin-Hai Ye; Jia Fan; Zhi-Quan Wu; Xin-Da Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2005-01-21       Impact factor: 4.553

Review 5.  Surgical treatment for liver cancer.

Authors:  Nicole C Tsim; Adam E Frampton; Nagy A Habib; Long R Jiao
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 6.  Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation.

Authors:  William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2010-04-20       Impact factor: 5.344

7.  Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma.

Authors:  Timothy M Pawlik; Ronnie T Poon; Eddie K Abdalla; Juan M Sarmiento; Iwao Ikai; Steven A Curley; David M Nagorney; Jacques Belghiti; Irene Oi-Lin Ng; Yoshio Yamaoka; Gregory Y Lauwers; Jean-Nicolas Vauthey
Journal:  J Gastrointest Surg       Date:  2004-11       Impact factor: 3.452

8.  Role of surgical resection for multiple hepatocellular carcinomas.

Authors:  Sung Hoon Choi; Gi Hong Choi; Seung Up Kim; Jun Yong Park; Dong Jin Joo; Man Ki Ju; Myoung Soo Kim; Jin Sub Choi; Kwang Hyub Han; Soon Il Kim
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

Review 9.  Value of radiofrequency ablation in the treatment of hepatocellular carcinoma.

Authors:  Kai Feng; Kuan-Sheng Ma
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

10.  Improved long-term survival after major resection for hepatocellular carcinoma: a multicenter analysis based on a new definition of major hepatectomy.

Authors:  Andreas Andreou; Jean-Nicolas Vauthey; Daniel Cherqui; Giuseppe Zimmitti; Dario Ribero; Mark J Truty; Steven H Wei; Steven A Curley; Alexis Laurent; Ronnie T Poon; Jacques Belghiti; David M Nagorney; Thomas A Aloia
Journal:  J Gastrointest Surg       Date:  2012-09-05       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.